

# ReleaseNF® Anti-Infection Silicone Foley Catheter

Proven to reduce the incidence of catheter-acquired urinary tract infections

Rochester Medical®



## PRODUCT DESCRIPTION

ReleaseNF is the only Foley catheter to deliver an anti-infective agent into the aqueous environment of the urethral tract. Unlike coated catheters that only help to prevent colonisation of the catheter surface, ReleaseNF is designed to elute nitrofurazone over a period of time to provide site-specific prophylaxis against catheter-associated urinary tract infections (CAUTIs). A randomised, controlled clinical study with 344 patients showed a 90% reduction in bacterial catheter-associated urinary tract infection after three days compared to a standard silicone Foley catheter.

## INDICATIONS

ReleaseNF Anti-Infection Foley Catheter is indicated wherever a silicone Foley catheter would be chosen for the management of urinary incontinence or bladder drainage. The use of indwelling catheters should only be considered after all other

possible approaches to care have been reviewed. Nitrofurazone is a nitrofurantoin derivative similar to the urinary antiseptic nitrofurantoin that has been used for treating urinary tract infections for over 40 years. It is a safe, effective, synthetic, anti-microbial agent with a broad spectrum, including most gram-positive bacteria and facultative gram-negative bacilli. Nitrofurazone is non-systemic and adverse events are very rare, with a low incidence of sensitisation. Acquired resistance of bacteria to nitrofurans during therapy has not appeared on a significant scale in over 60 years of use. The most likely reason for the lack of acquired resistance is the multiple mechanisms of action against bacteria.

## CONTRAINDICATIONS

Not for use on individuals with known sensitivity to nitrofurazone.

## METHOD OF USE

Catheterisation is a sterile procedure using an aseptic technique. Hands must be thoroughly washed and a no-touch technique is essential to ensure that hands do not contaminate sterile objects or the patient. Local policies and procedures should be followed in all cases.

## SIZES

ReleaseNF is available in Standard (male) length with a 10ml balloon in sizes 12CH to 26CH and with a 30ml balloon in sizes 16CH to 26CH.

## REFERENCES

- Maki DG et al (1997) *A report on the Randomised, Controlled Trial of the Nitrofurazone Impregnated, Anti-bacterial, Indwelling Foley Catheter*. April. Report on file at Rochester Medical Corporation
- McCosker CC, Fitzpatrick PM (1994). Nitrofurantoin: Mechanism of action and implications for resistance development in common uropathogens. *J Antimicrob Chemotherap* **33(Suppl A)**: 23–30
- Guay DR (2001) An Update on the role of nitrofurans in the management of urinary tract infections. *Drugs* **6(3)**: 12
- Stensballe J, Tvede M, Looms D et al (2007) Infection Risk with nitrofurazone-impregnated urinary catheters in trauma patients: a randomized trial. *Ann Int Med* **147(5)**: 285–93

## ANTIBACTERIAL ACTIVITY

*Multi-drug resistant	ACTIVITY AGAINST CAUTI PATHOGENS			
	Release NF		Silver Hydrogel	
	Inhibition of:		Inhibition of:	
CAUTI PATHOGENS	Susceptible	MDR*	Susceptible	MDR*
<i>Escherichia coli</i>	100%	100%	0%	0%
<i>Klebsiella pneumoniae</i>	100%	100%	0%	0%
<i>Clostridium freundii</i>	100%	100%	0%	0%
<i>Staphylococcus aureus</i>	100%	100%	100%	100%
<i>Coagulase-negative Staphylococcus</i>	100%	100%	25%	75%
<i>Enterococcus faecium</i>	100%	0%	0%	0%

Johnson JR et al (1999) Activities of a nitrofurazone-containing urinary catheter & a silver hydrogel catheter against multi-drug resistant bacteria characteristic of CAUTI. *Antimicrob Agents Chemotherap* **43(12)**: 2990–5